Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD. (ScanCLAD)

Vastra Gotaland Region

Status: Active, not recruiting

Conditions: Allografts; Lung Transplantation

Treatments: Drug: Tacrolimus; Drug: Cyclosporine; Drug: Rabbit Anti thymocyte globulin; Drug: Corticosteroids; Drug: Mycophenolate mofetil (MMF)

Study type: Interventional

Funder types: Other

Identifiers

NCT02936505

Version 8.0

2021-05380-02 (amendement) (Other Identifier)

2019-06057 (amendement) (Other Identifier)

T-798-16 (amendement) (Other Identifier)

T 055-18 (amendement) (Other Identifier)

T002-17 (amendement) (Other Identifier)

T568-18 (amendement) (Other Identifier)

2015-004137-27 (EudraCT Number)

154-16 (Other Identifier)

Details and patient eligibility

About

A controlled randomized, open-label, multi-centre study evaluating if an immunosuppressive protocol, based on ATG-induction, once daily tacrolimus-dose (Advagraf®), mycophenolate mofetil and corticosteroid reduces the incidence of chronic lung allograft dysfunction (CLAD) after lung transplantation, in comparison with a standard cyclosporin-based protocol.

Full description

Study purpose:

To evaluate whether the use of a once-daily tacrolimus-dose regimen (Advagraf®), based on anti-thymocyte globulin (Thymoglobulin®) induction, mycophenolate mofetil (MMF) and corticosteroids, reduces the cumulative incidence of CLAD after de novo lung transplantation at 36 months, in comparison with a twice-daily cyclosporin-based protocol, otherwise identical between groups.

Enrollment: 249 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

1. Male or female lung recipients 18-70 years of age undergoing primary double (including size reduction) lung transplantation.
2. Patient willing and capable of giving written informed consent for study participation and anticipated to be able to participate in the study for 36 months.

Exclusion Criteria

1. Recipients of multiorgan transplant, and or previously transplanted with any organ, including previous lung transplantation.
2. Patients with hypersensitivity to, or other reasons to not be able to take the immunosuppressive drugs used in the study.
3. Donor lung cold ischemic time > 12 hours.
4. Patients who previously have been treated with anti-thymocyte globulin preparations (e.g. ATG-Fresenius®, Thymoglobulin®).
5. Patients who are recipients of ABO-incompatible transplants.
6. Patients with platelet count < 50,000/mm3 at the evaluation before transplantation.
7. Patients who are unlikely to comply with the study requirements.
8. Patients, and/or those receiving organs from donors, who are positive for HIV, Hepatitis B surface antigen or Hepatitis C virus.
9. Patients with donor greater than 75 years.
10. Patient who have received an unlicensed drug or therapy within one month prior to study entry or if such therapy is to be instituted post-transplantation.
11. Patient unable to participate in the study for the full 36-month period
12. Patients with any past (within the past 3-5 years) or present malignancy (other than excised basal cell carcinoma).
13. Females capable of becoming pregnant must have a negative pregnancy test prior to randomization.

Females are recommended to practice a medically approved method of birth control for the duration of the study and a period of 8 weeks following discontinuation of study medication, even where there has been a history of infertility

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

249 participants in 2 patient groups

Arm A:Cyclosporine

Active Comparator group

Description:

Group A: Cyclosporine A, Mycophenolate mofetil (MMF) and corticosteroids according to local practice and approved label.

Treatment:

Drug: Mycophenolate mofetil (MMF)

Drug: Corticosteroids

Drug: Rabbit Anti thymocyte globulin

Drug: Cyclosporine

Arm B:Tacrolimus

Experimental group

Description:

Group B: Tacrolimus (Advagraf), Mycophenolate mofetil (MMF) and corticosteroids.

Treatment:

Drug: Mycophenolate mofetil (MMF)

Drug: Corticosteroids

Drug: Rabbit Anti thymocyte globulin

Drug: Tacrolimus